Dormond O - Search Results

1

Immune cell infiltration in colonic cancer: correlation between biopsy and surgical specimens.

Bordry N, Germann M, Foukas PG, Sempoux C, Yan P, Dormond O, Speiser DE, Demartines N, Sauvain MO. Bordry N, et al. Among authors: dormond o. Br J Surg. 2021 Apr 30;108(4):346-350. doi: 10.1093/bjs/znaa142. Br J Surg. 2021. PMID: 33792645 No abstract available.

2

Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo.

Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O. Roulin D, et al. Among authors: dormond meuwly a, dormond o. Mol Cancer. 2010 Mar 12;9:57. doi: 10.1186/1476-4598-9-57. Mol Cancer. 2010. PMID: 20226010 Free PMC article.

3

Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin.

Abdelnour-Berchtold E, Cerantola Y, Roulin D, Dormond-Meuwly A, Demartines N, Dormond O. Abdelnour-Berchtold E, et al. Among authors: dormond meuwly a, dormond o. Anticancer Res. 2010 Mar;30(3):799-804. Anticancer Res. 2010. PMID: 20392999

4

Targeting the JNK signaling pathway potentiates the antiproliferative efficacy of rapamycin in LS174T colon cancer cells.

Benoit M, Dormond-Meuwly A, Demartines N, Dormond O. Benoit M, et al. Among authors: dormond meuwly a, dormond o. J Surg Res. 2011 May 15;167(2):e193-8. doi: 10.1016/j.jss.2011.01.015. Epub 2011 Feb 5. J Surg Res. 2011. PMID: 21324487

5

ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.

Roulin D, Demartines N, Dormond O. Roulin D, et al. Among authors: dormond o. Biochem Soc Trans. 2011 Apr;39(2):492-4. doi: 10.1042/BST0390492. Biochem Soc Trans. 2011. PMID: 21428926 Review.

6

The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.

Dormond-Meuwly A, Roulin D, Dufour M, Benoit M, Demartines N, Dormond O. Dormond-Meuwly A, et al. Among authors: dormond o. Biochem Biophys Res Commun. 2011 Apr 22;407(4):714-9. doi: 10.1016/j.bbrc.2011.03.086. Epub 2011 Mar 23. Biochem Biophys Res Commun. 2011. PMID: 21439267

7

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.

Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O. Roulin D, et al. Among authors: dormond meuwly a, dormond o. Mol Cancer. 2011 Jul 26;10:90. doi: 10.1186/1476-4598-10-90. Mol Cancer. 2011. PMID: 21791089 Free PMC article.

8

Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.

Blaser B, Waselle L, Dormond-Meuwly A, Dufour M, Roulin D, Demartines N, Dormond O. Blaser B, et al. Among authors: dormond meuwly a, dormond o. BMC Cancer. 2012 Mar 8;12:86. doi: 10.1186/1471-2407-12-86. BMC Cancer. 2012. PMID: 22401294 Free PMC article.

9

Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects.

Dufour M, Dormond-Meuwly A, Pythoud C, Demartines N, Dormond O. Dufour M, et al. Among authors: dormond meuwly a, dormond o. Biochem Biophys Res Commun. 2013 Aug 16;438(1):32-7. doi: 10.1016/j.bbrc.2013.07.014. Epub 2013 Jul 15. Biochem Biophys Res Commun. 2013. PMID: 23867821

10

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives.

Dufour M, Dormond-Meuwly A, Demartines N, Dormond O. Dufour M, et al. Among authors: dormond meuwly a, dormond o. Cancers (Basel). 2011 May 24;3(2):2478-500. doi: 10.3390/cancers3022478. Cancers (Basel). 2011. PMID: 24212820 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

74 results

Search Page

Filters